Stock Events

Stock Events

ImageneBio 

$5.05
0
+$0.05+1% Wednesday 20:00

Statistics

Day High
5.14
Day Low
4.92
52W High
18
52W Low
3.94
Volume
19,063
Avg. Volume
37,136
Mkt Cap
53.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q2 2025
Q3 2025
Q4 2025
Next
-2.91
-2.05
-1.19
-0.33
Expected EPS
-0.666667
Actual EPS
N/A

Financials

-6,549.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.6MRevenue
-104.79MNet Income

Analyst Ratings

$16.00Average Price Target
The highest estimate is 30.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
0%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma is involved in the development of drugs for cancer, competing in the same therapeutic area as Ikena Oncology.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals works on metabolic immuno-oncology, which competes with Ikena's cancer metabolism programs.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation has a broad portfolio in oncology, including targeted therapies, making it a direct competitor.
Kura Oncology
KURA
Mkt Cap891.41M
Kura Oncology focuses on precision medicine in oncology, directly competing with Ikena's approach to cancer treatment.
Xencor
XNCR
Mkt Cap994.24M
Xencor is involved in engineering monoclonal antibodies for the treatment of cancer, competing in the biologics space with Ikena.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer, offering competitive alternatives to Ikena's treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of cancer therapies including areas Ikena Oncology targets.

About

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
Show more...
CEO
Ms. Erin Butler
Employees
10
Country
US
ISIN
US45175G2075

Listings

XNAS
US
IMA
BOATS
BOATS
IMA.BOATS

0 Comments

Share your thoughts

FAQ

What is ImageneBio stock price today?▼
The current price of IMA is $5.05 USD — it has increased by +1% in the past 24 hours. Watch ImageneBio stock price performance more closely on the chart.
What is ImageneBio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ImageneBio stocks are traded under the ticker IMA.
What is ImageneBio market cap?▼
Today ImageneBio has the market capitalization of 53.8M
When is the next ImageneBio earnings date?▼
ImageneBio is going to release the next earnings report on May 12, 2026.
What were ImageneBio earnings last quarter?▼
IMA earnings for the last quarter are -0.62 USD per share, whereas the estimation was -1.38 USD resulting in a +55.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ImageneBio revenue for the last year?▼
ImageneBio revenue for the last year amounts to 1.6M USD.
What is ImageneBio net income for the last year?▼
IMA net income for the last year is -104.79M USD.
How many employees does ImageneBio have?▼
As of April 02, 2026, the company has 10 employees.
When did ImageneBio complete a stock split?▼
The last stock split for ImageneBio was on July 28, 2025 with a ratio of 1:12.
Where is ImageneBio headquartered?▼
ImageneBio is headquartered in San Diego, US.